Get Flat 20% Discount on All Medications
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Glenmark Pharma > December 29, 2010

      Glenmark gets USFDA nod for lithium carbonate


      The US subsidiary of Glenmark Generics today said that they have been granted final abbreviated new drug application (ANDA) approval by the United States Food and Drug Administration (USFDA) for Lithium Carbonate 300 mg extended-release tablets. The company said that it will commence the marketing and distribution of the product immediately.

      Lithium Carbonate 300 mg extended-release tablets are Glenmark's generic version of Lithobid by Noven Therapeutics which is indicated for manic episodes of bipolar disorder. According to IMS Health, the drug had total sales of $21 million for 12 months ending September. Glenmark will be one of the two generic players of this drug in the market.

      Glenmark is currently authorised to distribute 66 products in the United States. The company said that it will maintain an aggressive ANDA filing strategy and will also explore partnerships to augment its portfolio.

      Dec 29, 2010


      Share this Article!

    Back to top^